QUEST PATENT RESEARCH CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that QUEST PATENT RESEARCH CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.05M | Apr 1, 2022 |
| FY2021 | Dec 31, 2020 | $5.49M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $4.14M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $7.07M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.23M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $1.26M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $498.4K | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $940.6K | Apr 1, 2016 |
| FY2014 | Dec 31, 2013 | $74.6K | Aug 18, 2015 |
| FY2013 | Dec 31, 2012 | $261.0K | Apr 10, 2015 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $14.2K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $18.4K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $33.0K | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $22.7K | Apr 1, 2016 |
| FY2014 | Dec 31, 2013 | $29.6K | Aug 18, 2015 |
| FY2013 | Dec 31, 2012 | $43.5K | Apr 10, 2015 |
| FY2012 | Sep 30, 2012 | $10.8K | Dec 15, 2014 |
| FY2012 | Jun 30, 2012 | $5.7K | Dec 15, 2014 |
| FY2012 | Mar 31, 2012 | $14.8K | Dec 15, 2014 |
| FY2012 | Dec 31, 2011 | $49.2K | Dec 15, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.07M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $950.9K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $6.25M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $147.5K | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $735.1K | Mar 31, 2023 |
| FY2014 | Dec 31, 2014 | $571.6K | Aug 18, 2015 |
| FY2014 | Dec 31, 2013 | $52.5K | Aug 18, 2015 |
| FY2013 | Dec 31, 2012 | $183.4K | Apr 10, 2015 |
| FY2012 | Sep 30, 2012 | $107.6K | Dec 15, 2014 |
| FY2012 | Jun 30, 2012 | ($28.9K) | Dec 15, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.65M | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | ($753.5K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.15M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($1.31M) | Apr 15, 2021 |
| FY2020 | Dec 31, 2019 | ($1.31M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.11M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($1.17M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($956.0K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($328.0K) | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | ($161.5K) | Apr 1, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.69M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.85M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $3.51M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($1.83M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($3.11M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($718.7K) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($469.4K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $29.4K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($545.7K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($676.7K) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2010 | $1.0K | Dec 15, 2014 |
| FY2012 | Dec 31, 2009 | $14.2K | Dec 15, 2014 |
| FY2012 | Dec 31, 2008 | $24.7K | Dec 15, 2014 |
| FY2012 | Dec 31, 2006 | $14.2K | Dec 15, 2014 |
| FY2012 | Dec 31, 2005 | $86.3K | Dec 15, 2014 |
| FY2012 | Dec 31, 2004 | $86.3K | Dec 15, 2014 |
| FY2012 | Dec 31, 2003 | $122.1K | Dec 15, 2014 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.62M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.80M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.74M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.98M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $3.85M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.51M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.22M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $957.6K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $939.4K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $767.0K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.92M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($390.3K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.93M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($914.2K) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($49.7K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($246.3K) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $746.5K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($378.6K) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($167.8K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($373.2K) | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.44M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.54M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.28M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.23M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $816.6K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.49M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $5.16M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.21M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.63M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $2.32M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.63M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $12.24M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $13.52M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $9.79M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $8.74M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.33M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $11.01M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $6.75M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.06M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $3.66M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.19M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($8.70M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($6.24M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($8.56M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($7.93M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.84M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($5.85M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($4.54M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($2.43M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($1.34M) | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.87M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($26.38M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($23.91M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($26.19M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($25.44M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($21.28M) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($19.97M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($18.66M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($16.55M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($15.38M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $192.6K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $482.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $563.5K | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $90.6K | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $264.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $247.9K | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $537.2K | Apr 15, 2021 |
| FY2020 | Dec 31, 2018 | $166.9K | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $165.5K | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $208.3K | Apr 16, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $1.25M | Apr 1, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 14, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 14, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.33M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 5.33M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 5.33M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 5.33M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | 5.33M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 383.04M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | 383.04M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 383.04M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 383.04M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 313.04M | Apr 2, 2018 |